Wolfgang Friess

Wolfgang Friess


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
ETEduard Trenkenschuh
Eduard Trenkenschuh
WFWolfgang Friess
Wolfgang Friess

26 July 2021 in Advanced Healthcare Materials
Verified
Journal Article
Open access
PDF file
ETEduard Trenkenschuh
Eduard Trenkenschuh
MRMaximilian Richter
Maximilian Richter
EHEilien Heinrich
Eilien Heinrich
MKMarcus Koch
Marcus Koch
GFGregor Fuhrmann
Gregor Fuhrmann
WFWolfgang Friess
Wolfgang Friess
Extracellular vesicles (EV) are an emerging technology as immune therapeutics and drug delivery vehicles. However, EVs are usually stored at −80 °C which limits potential clinical applicability. Freeze‐drying of EVs striving for long‐term stable formulations is therefore studied. The most appropriate formulation parameters are identified in freeze‐thawing studies with two different EV types. After a freeze‐drying feasibility study, four lyophilized EV formulations are tested for storage stability for up to 6 months. Freeze‐thawing studies revealed improved colloidal EV stability in presence of sucrose or potassium phosphate buffer instead of sodium phosphate buffer or phosphate‐buffered saline. Less aggregation and/or vesicle fusion occurred at neutral pH compared to slightly acidic or alkaline pH. EVs colloidal stability can be most effectively preserved by addition of low amounts of poloxamer 188. Polyvinyl pyrrolidone failed to preserve EVs upon freeze‐drying. Particle size and concentration of EVs are retained over 6 months at 40 °C in lyophilizates containing 10 mm K‐ or Na‐phosphate buffer, 0.02% poloxamer 188, and 5% sucrose. The biological activity of associated beta‐glucuronidase is maintained for 1 month, but decreased after 6 months. Here optimized parameters for lyophilization of EVs that contribute to generate long‐term stable EV formulations are presented.

1 March 2002 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
PDF file
WFWolfgang Friess
Wolfgang Friess
MSMonika Schlapp
Monika Schlapp

1 January 2014 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
SCSarah Claus
Sarah Claus
CWClaudius Weiler
Claudius Weiler
JSJoerg Schiewe
Joerg Schiewe
WFWolfgang Friess
Wolfgang Friess

1 June 2019 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
CDCorinna Duerr
Corinna Duerr
WFWolfgang Friess
Wolfgang Friess

1 June 2006 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
WFWolfgang Friess
Wolfgang Friess
MSMonika Schlapp
Monika Schlapp